Prostate Cancer Clinical Trial

Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)

Summary

This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate. The investigators have hypothesized that this treatment technique will effectively control the prostate cancer while minimizing the side effects.

View Full Description

Full Description

Objectives:

Primary

-Clinically assess the early toxicity of SBRT with integrated boost for clinically localized prostate cancer

Secondary

Determine the technical feasibility of stereotactic body radiotherapy (SBRT) with integrated boost for clinically localized prostate cancer

Determine the treatment planning and dosimetric feasibility
Evaluate the treatment delivery quality assurance
Clinically assess early efficacy, late toxicity, and quality of life for patients receiving SBRT with integrated boost for clinically localized prostate cancer

Patients will undergo 5 total radiation treatments over 7-17 day period.

Patients will be asked to complete American Urological Association Symptom Index (AUA SI), Sexual Health Inventory of Men (SHIM), and the Expanded Prostate Index Composite (EPIC)questionnaires. The EPIC assesses bowel, urinary, and sexual function. These questionnaires will be completed at the following time points: Baseline, AUA SI will be collected on the last day of treatment, and every 3 months for the first year following the start of radiation, then every 6 months for year 2.

After completion of study therapy, patients are followed-up every 3 months for the first year, then every 6 months for year 2.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

All patients must have Histologically confirmed prostate adenocarcinoma, with biopsies obtained within twelve months of patient registration
NCCN risk category very low, low, or intermediate risk
Combined Gleason score <7
PSA within three months of enrollment < 20ng/ml
Clinical stage T1a-c N0M0 or clinical stage T2aN0M0
Life expectancy > 5 years
Risk of malignant lymph node involvement < 15% as calculated on Partin tables
Karnofsky performance status (KPS) > 60
Age > 19 years
Subjects given written informed consent

Exclusion Criteria:

History of inflammatory bowel disease
Prior radical prostate surgery, transurethral resection of the prostate(TURP), or prostate cryotherapy
Patients using immunosuppressive medications or other medications that may increase radiation toxicity such as methotrexate, sirolimus, tacrolimus, or colchicine that are unable to discontinue these medications during SBRT course. Use of corticosteroids are not considered an exclusion criteria.
Platelet count < 70
Patients unable to discontinue anti-platelet or anti-coagulant medicine such as clopidogrel, dabigatran, warfarin, or low molecular weight heparin. Use of aspirin is not an exclusion criteria.
Pre-SBRT prostate volume > 120 cc as estimated by trans-rectal ultrasound at time of prostate biopsy (TRUS biopsy).
Risk of malignant lymph node involvement > 15% as calculated on Partin tables.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

26

Study ID:

NCT01856855

Recruitment Status:

Completed

Sponsor:

John Fiveash, MD

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Hazelrig-Salter Radiation Oncology Center
Birmingham Alabama, 35249, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

26

Study ID:

NCT01856855

Recruitment Status:

Completed

Sponsor:


John Fiveash, MD

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.